Eric Holmgren

18.4k total citations · 5 hit papers
46 papers, 14.1k citations indexed

About

Eric Holmgren is a scholar working on Oncology, Pulmonary and Respiratory Medicine and Molecular Biology. According to data from OpenAlex, Eric Holmgren has authored 46 papers receiving a total of 14.1k indexed citations (citations by other indexed papers that have themselves been cited), including 30 papers in Oncology, 11 papers in Pulmonary and Respiratory Medicine and 8 papers in Molecular Biology. Recurrent topics in Eric Holmgren's work include Cancer Treatment and Pharmacology (19 papers), Colorectal Cancer Treatments and Studies (17 papers) and Statistical Methods in Clinical Trials (7 papers). Eric Holmgren is often cited by papers focused on Cancer Treatment and Pharmacology (19 papers), Colorectal Cancer Treatments and Studies (17 papers) and Statistical Methods in Clinical Trials (7 papers). Eric Holmgren collaborates with scholars based in United States, Australia and New Zealand. Eric Holmgren's co-authors include Fairooz F. Kabbinavar, William Novotny, Louis Fehrenbacher, Herbert I. Hurwitz, W. Heim, John D. Hainsworth, Jordan Berlin, Thomas H. Cartwright, Ari David Baron and Napoleone Ferrara and has published in prestigious journals such as New England Journal of Medicine, Journal of Clinical Oncology and Journal of the American Statistical Association.

In The Last Decade

Eric Holmgren

44 papers receiving 13.7k citations

Hit Papers

5 papers align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Bevacizumab plus Irinotecan, Fluorouracil, and Leucovorin for Metastatic Colorectal Cancer

2004 8.4k citations Herbert I. Hurwitz, Louis Fehrenbacher et al. New England Journal of Medicine profile →
Randomized Phase II Trial Comparing Bevacizumab Plus Carboplatin and Paclitaxel With Carboplatin and Paclitaxel Alone in Previously Untreated Locally Advanced or Metastatic Non-Small-Cell Lung Cancer

2004 1.5k citations David H. Johnson, Louis Fehrenbacher et al. Journal of Clinical Oncology profile →
Phase I Safety and Pharmacokinetic Study of Recombinant Human Anti-Vascular Endothelial Growth Factor in Patients With Advanced Cancer

2001 744 citations Michael S. Gordon, Kim Margolin et al. Journal of Clinical Oncology profile →
Arterial Thromboembolic Events in Patients with Metastatic Carcinoma Treated with Chemotherapy and Bevacizumab

2007 725 citations Frank A. Scappaticci, Jamey Skillings et al. JNCI Journal of the National Cancer Institute profile →
Bevacizumab in Combination With Fluorouracil and Leucovorin: An Active Regimen for First-Line Metastatic Colorectal Cancer

2005 550 citations Herbert I. Hurwitz, Louis Fehrenbacher et al. Journal of Clinical Oncology profile →

Peers

Countries citing papers authored by Eric Holmgren

Since Specialization

Citations

This map shows the geographic impact of Eric Holmgren's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Eric Holmgren with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Eric Holmgren more than expected).

Fields of papers citing papers by Eric Holmgren

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Eric Holmgren. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Eric Holmgren. The network helps show where Eric Holmgren may publish in the future.

Co-authorship network of co-authors of Eric Holmgren

This figure shows the co-authorship network connecting the top 25 collaborators of Eric Holmgren. A scholar is included among the top collaborators of Eric Holmgren based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Eric Holmgren. Eric Holmgren is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work	Indexed citations
1	Zanubrutinib for the treatment of patients with Waldenström macroglobulinemia: 3 years of follow-up 2020 ·Blood ·Judith Trotman, Stephen Opat, David Gottlieb, David Simpson, Paula Marlton, Gavin Cull, Javier Muñoz, Alessandra Tedeschi, Andrew W. Roberts, John F. Seymour, Siminder Atwal, Yiling Yu, William Novotny, Eric Holmgren, (unknown), James Hilger, Jane Huang, Constantine S. Tam	73
2	The application of group sequential stopping boundaries to evaluate the treatment effect of an experimental agent across a range of biomarker expression 2017 ·Contemporary Clinical Trials ·Eric Holmgren	3
3	Results of a randomized phase II trial of an anti-notch 2/3, tarextumab (OMP-59R5, TRXT, anti-Notch2/3), in combination with nab-paclitaxel and gemcitabine (Nab-P+Gem) in patients (pts) with untreated metastatic pancreatic cancer (mPC). 2017 ·Journal of Clinical Oncology ·Eileen M. O’Reilly, Vaibhav Sahai, Johanna C. Bendell, Andrea J. Bullock, Noelle K. LoConte, Hassan Hatoum, Paul S. Ritch, Hugo Hool, Joseph W. Leach, James F. Sanchez, Davendra Sohal, John H. Strickler, Ravindranath Patel, Andrea Wang‐Gillam, Irfan Firdaus, Ann M. Kapoun, Eric Holmgren, Lei Zhou, Jakob Dupont, Vincent J. Picozzi	16
4	Independent Adjudication of Symptomatic Heart Failure With the Use of Doxorubicin and Cyclophosphamide Followed by Trastuzumab Adjuvant Therapy: A Combined Review of Cardiac Data From the National Surgical Adjuvant Breast and Bowel Project B-31 and the North Central Cancer Treatment Group N9831 Clinical Trials 2010 ·Journal of Clinical Oncology ·Stuart D. Russell, Kimberly Blackwell, Julia Lawrence, John Pippen, Matthew T. Roe, (unknown), Virginia Paton, Eric Holmgren, Kenneth W. Mahaffey	149
5	Quantifying the usefulness of PD biomarkers in Phase 2 screening trials of oncology drugs 2008 ·Statistics in Medicine ·Eric Holmgren	1
6	An adaptive Simon Two-Stage Design for Phase 2 studies of targeted therapies 2007 ·Contemporary Clinical Trials ·(unknown), Eric Holmgren	43
7	Arterial Thromboembolic Events in Patients with Metastatic Carcinoma Treated with Chemotherapy and Bevacizumab breakdown → 2007 ·JNCI Journal of the National Cancer Institute ·Frank A. Scappaticci, Jamey Skillings, Scott N. Holden, Hans Peter Gerber, Kathy D. Miller, Fairooz F. Kabbinavar, Emily K. Bergsland, Jenny Ngai, Eric Holmgren, Jia Wang, H. Hurwitz	725
8	Are Phase 2 screening trials in oncology obsolete? 2007 ·Statistics in Medicine ·Eric Holmgren	3
9	Endpoints for agents that slow tumor growth 2006 ·Contemporary Clinical Trials ·Ron Yu, Eric Holmgren	12
10	Association of k-ras, b-raf, and p53 Status With the Treatment Effect of Bevacizumab 2005 ·JNCI Journal of the National Cancer Institute ·William L. Ince, Adrian M. Jubb, Scott N. Holden, Eric Holmgren, (unknown), (unknown), Herbert I. Hurwitz, Fairooz F. Kabbinavar, William Novotny, Kenneth J. Hillan, Hartmut Koeppen	262
11	Minimally important differences were estimated for the Functional Assessment of Cancer Therapy–Colorectal (FACT-C) instrument using a combination of distribution- and anchor-based approaches 2005 ·Journal of Clinical Epidemiology ·Kathleen J. Yost, David Cella, Anita Chawla, Eric Holmgren, David T. Eton, John Z. Ayanian, David West	140
12	Impact of Vascular Endothelial Growth Factor-A Expression, Thrombospondin-2 Expression, and Microvessel Density on the Treatment Effect of Bevacizumab in Metastatic Colorectal Cancer 2005 ·Journal of Clinical Oncology ·Adrian M. Jubb, Herbert I. Hurwitz, Wei Bai, Eric Holmgren, (unknown), (unknown), Fairooz F. Kabbinavar, Scott N. Holden, William Novotny, Gretchen Frantz, Kenneth J. Hillan, Hartmut Koeppen	305
13	Randomized Phase II Trial Comparing Bevacizumab Plus Carboplatin and Paclitaxel With Carboplatin and Paclitaxel Alone in Previously Untreated Locally Advanced or Metastatic Non-Small-Cell Lung Cancer breakdown → 2004 ·Journal of Clinical Oncology ·David H. Johnson, Louis Fehrenbacher, William Novotny, Roy S. Herbst, John Nemunaitis, David M. Jablons, Corey J. Langer, Russell F. DeVore, Jacques Gaudreault, Lisa A. Damico, Eric Holmgren, Fairooz F. Kabbinavar	1516
14	Bevacizumab does not increase bleeding in patients with metastatic colorectal cancer receiving concurrent anticoagulation 2004 ·Journal of Clinical Oncology ·J. Hambleton, William Novotny, Herbert I. Hurwitz, Louis Fehrenbacher, Thomas H. Cartwright, John D. Hainsworth, W. Heim, Jordan Berlin, Fairooz F. Kabbinavar, Eric Holmgren	45
15	Bevacizumab plus Irinotecan, Fluorouracil, and Leucovorin for Metastatic Colorectal Cancer breakdown → 2004 ·New England Journal of Medicine ·Herbert I. Hurwitz, Louis Fehrenbacher, William Novotny, Thomas H. Cartwright, John D. Hainsworth, W. Heim, Jordan Berlin, Ari David Baron, (unknown), Eric Holmgren, Napoleone Ferrara, Gwen Fyfe, Beth Rogers, Robert W. Ross, Fairooz F. Kabbinavar	8433
16	150 Molecular tumor characteristics and response to bevacizumab plus irinotecan/5-fluorouracil/leucovorin in metastatic colorectal cancer 2004 ·European Journal of Cancer Supplements ·Hartmut Koeppen, Will Ince, Eric Holmgren, (unknown), (unknown), Ruitao Zhang, William Novotny, Kenneth J. Hillan	2
17	Phase I Safety and Pharmacokinetic Study of Recombinant Human Anti-Vascular Endothelial Growth Factor in Patients With Advanced Cancer breakdown → 2001 ·Journal of Clinical Oncology ·Michael S. Gordon, Kim Margolin, Moshe Talpaz, George W. Sledge, Eric Holmgren, Robert S. Benjamin, (unknown), S. Shak, Daniel C. Adelman	744
18	Intracoronary administration of recombinant human vascular endothelial growth factor to patients with coronary artery disease 2001 ·American Heart Journal ·Timothy D. Henry, Krishna J. Rocha‐Singh, Jeffrey M. Isner, Dean J. Kereiakes, Frank J. Giordano, Michael Simons, Douglas W. Losordo, Robert C. Hendel, Robert O. Bonow, (unknown), Thomas F. Zioncheck, Eric Holmgren, Edward R. McCluskey	166
19	A Phase II Trial of Humanized Anti‐Vascular Endothelial Growth Factor Antibody for the Treatment of Androgen‐Independent Prostate Cancer 2001 ·David Reese, (unknown), (unknown), William Novotny, Eric Holmgren, Eric J. Small	51
20	The P-P Plot as a Method for Comparing Treatment Effects 1995 ·Journal of the American Statistical Association ·Eric Holmgren	5

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact